Sat 17 Oct 2026
All official websites of government entities in the Kingdom of Saudi Arabia end with.gov.sa.
Ensure the website is using the HTTPS protocol.
Registered with the Digital Government Authority under number:
| Study Title | Study Sponsor | Status | Study Drug | Trial Phase | Study Protocol Number | Site |
|---|---|---|---|---|---|---|
| A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants with Moderately to Severely Active Systemic Lupus Erythematosus | UCB Biopharma SRL/ PDC | Ongoing | Dapirolizumab (BIIB133) | 3 | SL0044 | King Fahad Medical City (Riyadh) |
| A Phase III Randomized, Double-blind, Placebo-controlled Multicenter Master Protocol to Evaluate the Efficacy and Safety of Elecoglipron in Participants with Obesity or Overweight with or without Type 2 Diabetes Mellitus (Embold) | Astrazeneca UK Ltd. | Ongoing | Elecoglipron | 3 | D7260C00015 | King Fahad Specialist Hospital (Dammam) |
| Levofloxacin Versus Rifabutin Based Triple Therapy as A Salvage Treatment for Helicobacter Pylori Eradication: Prospective Randomized Trial | King Faisal Specialist Hospital and Research Center (Riyadh) | Ongoing | Levofloxacin / Rifabutin | 3 | 2251618 | King Faisal Specialist Hospital and Research Center (Riyadh) |
| A Phase 1/2/3 Study to Evaluate the Safety, Tolerability, and Efficacy of VX-880 in Subjects Who Have Type 1 Diabetes Mellitus With Impaired Hypoglycemic Awareness and Severe Hypoglycemia | Vertex / CTI | Ongoing | VX 880 | 3 | VX20-880-101 | King Abdulaziz Hospital NG (Riyadh) |
| Evaluation of safety and efficacy of non-anesthesia provider-administered different anesthetic regimens during colonoscopy: a single center, prospective double blind, randomized study | PI initiated | Ongoing | Propofol | 4 | 6074515 | King Saud Hospital (Unaizah) |
| A global phase 3, randomised, double-blind and placebo-controlled study evaluating the efficacy and safety of etavopivat in adolescents and adults with sickle cell disease | Novo Nordisk | Ongoing | Etavopivat | 3 | NN7535-7807 | 1.King Faisal Specialist Hospital and Researech Center - Riyadh 2. National Guard Health Affairs - Alahsa 3.Imam Abdulrahman Bin Faisal University - Dammam 4. King Saud University Medical city - Riyadh 5.Prince Mohammed bin Fahad hospital- Qatif |
| Registry-based study of patients treated with exagamglogene autotemcel (exa-cel) in the Kingdom of Saudi Arabia | Vertex | Ongoing | Exagamglogene autotemcel (Casgevy) | 4 | 290-103 | - |
| A Phase II/III, Extension Study of Orally Administered PHA-022121 for Acute Treatment of Angioedema Attacks in Patients with Hereditary Angioedema due to C1-Inhibitor Deficiency (Type I or Type II (RAPIDe-2) | Pharvaris Netherlands B.V. | Ongoing | Deucrictibant | 2/3 | PHA022121-C303 | King Faisal Specialist Hospital and Research Center (Riyadh) |
| Patient and prescriber survey: effectiveness measures to investigate awareness, knowledge, and adherence to the additional risk minimisation measures (aRMM) of the patient reminder card for oral ambrisentan (PrVolibris®) | GSK | Ongoing | Ambrisentan | 4 | 221772 | King Abdullah International Medical Research Center– Jeddah |
| A Phase 3 Multicenter, Randomized, Double-Blind Placebo-Controlled Study to Evaluate the Efficacy and Safety of Lutikizumab in Adult and Adolescent Subjects with Moderate to Severe Hidradenitis Suppurativa | AbbVie Biopharmaceuticals GmbH ScientificOffice | Ongoing | Lutikizumab | 3 | M20-465 | King Khalid University Hospital (Riyadh), King Faisal Specialist Hospital and Research Center (Riyadh), King Faisal Specialist Hospital and Research Center (Jeddah), King Abdulaziz Medical City NG (Jeddah) |
Last update date: 06/10/2026 at 08:14 AM Saudi Arabia time
No feedback has been submitted for this page yet.
Comments and Suggestions
For any inquiries or comments about the government services, please fill in the required information.